Hisaka Capsule contains Polmacoxib 2 mg, a selective cyclooxygenase-2 (COX-2) inhibitor indicated for the management of pain and inflammation associated with osteoarthritis, rheumatoid arthritis, and other musculoskeletal disorders. Polmacoxib exerts its therapeutic effects by selectively inhibiting the COX-2 enzyme, thereby reducing the synthesis of prostaglandins involved in inflammation and pain, while sparing COX-1 activity to minimize gastrointestinal adverse effects commonly associated with non-selective NSAIDs. Hisaka Capsule is recommended for short-term symptomatic relief of mild to moderate pain and inflammation. The medication should be administered orally, with dosage and duration tailored according to the severity of symptoms and patient response. Caution is advised in patients with a history of cardiovascular disease, gastrointestinal bleeding, renal or hepatic impairment, and hypersensitivity to NSAIDs. Concomitant use with anticoagulants, corticosteroids, or other NSAIDs should be avoided to reduce the risk of adverse events. Common side effects may include dyspepsia, nausea, and headache. Patients are advised to report any signs of gastrointestinal bleeding, cardiovascular symptoms, or allergic reactions promptly. Hisaka Capsule should be used under medical supervision with regular monitoring to ensure safety and efficacy.